For this 4/20 enjoy FREE GROUND SHIPPING on all inventory orders, use code: Blinc420
Our sources in China have revealed that the Chinese government has just allowed three daughter companies of the pharmaceutical group Zhejiang Kangenbei from the Yunnan province to cultivate Cannabis for therapeutic use. They will be producing CBD from low THC plant varieties. This is an exclusive story from our partner in Europe, France Le Cannabiste.
07/24/2018 – New York, NY – Today, The Blinc Group’s Co-CEO is testifying at The Office of the U.S. Trade Representative (USTR) public hearings regarding proposed tariffs on approximately $16 billion worth of Chinese products.
These proposed tariffs increases – including HTS No. 8543709930 and HTS No. 8543709940 related to vapor product devices, batteries intended for use in vaping devices, and pods and cartridges – will do great harm to American businesses, medical marijuana patients, and adult use consumers while doing nothing to empower American companies to manufacture these products themselves.
SHOP
EXPLORE
CONNECT
CUSTOMER SERVICE
E-MAIL BY DEPARTMENT
Privacy Policy  |  Terms of Use
Copyright © 2023 The Blinc Group, Inc. All rights reserved.
